Dignitana Publishes Annual Report for 2017

Lund, Sweden3 April 2018Dignitana AB hereby publishes the annual report for 2017. The annual report is attached to this press release and can be downloaded from the website www.dignitana.se. You can also order a printed version via investorrelations@dignitana.com.Note: This report is published in Swedish.

Note: For a similar report in English, view the Dignitana 2017 Year End Report that was released 22 February 2018.


-----------------------------------

Dignitana AB publicerar årsredovisningen för 2017

 Lund, Sweden3 April 2018Dignitana AB offentliggör härmed årsredovisningen avseende 2017. Årsredovisningen finns som bilaga till detta pressmeddelande samt går att ladda ner från hemsidan, www.dignitana.se. Det går även att beställa en utskriven version via investorrelations@dignitana.com. 

Obs! Denna rapport är publicerad på svenska. För en liknande rapport på engelska, se Dignitana 2017 Year End Report som släpptes den 22 Februari 2018.

-----------------------------------


The above is information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, by the above contact, for publication at 8:05 CEST 3 April 2018.

Investor Relations

Melissa Bourestom                                       

Dignitana                                                       

00 1 773 387 8504                                         

investorrelations@dignitana.com                 

Media Contact   

Caren Browning  

King + Company

00 1 212 561 7464

caren.browning@kingcompr.com

About Dignitana AB (publ)

Dignitana is a Swedish public company based in Lund and manufacturer of the medical cooling device DigniCap®. Dignitana AB is listed on Nasdaq First North Stockholm and has appointed Erik Penser Bank as Certified Adviser. Headquartered in Dallas Texas, Dignitana, Inc. is the U.S. subsidiary of Dignitana AB. DigniCap®is a patented scalp cooling system that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and acceptable patient comfort.

 For more information visit www.dignitana.se  and www.dignicap.com.

Tags:

About Us

About Dignitana AB (publ)Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and acceptable patient comfort. Dignitana AB is listed on Nasdaq First North Stockholm in Sweden with headquarters in Lund, Sweden and operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Erik Penser Bank is Certified Adviser. Learn more at www.dignitana.se and www.dignicap.com.